NCT00719264 2017-03-20
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis
Phase 2 Completed
Novartis
Sanofi
Hoffmann-La Roche
Hoffmann-La Roche
sigma-tau i.f.r. S.p.A.